{"id":6646,"date":"2024-11-21T13:58:15","date_gmt":"2024-11-21T12:58:15","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6646"},"modified":"2025-04-28T21:35:19","modified_gmt":"2025-04-28T19:35:19","slug":"sars-cov-2-neutralising-antibody-bgb-dxp593-in-mild-to-moderate-covid-19-a-multicentre-randomised-double-blind-phase-2-trial","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/sars-cov-2-neutralising-antibody-bgb-dxp593-in-mild-to-moderate-covid-19-a-multicentre-randomised-double-blind-phase-2-trial\/","title":{"rendered":"SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6646","publication","type-publication","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6646"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}